相关实验视频

Updated: Jan 11, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

超越乌尔索多西胆酸:对初级胆道胆道炎的二线药物的全面审查

Vijay Lakshmanan¹, Liam Morris²

¹Hospital Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GBR.

|November 10, 2025

概括

像elafibranor和seladelpar这样的新疗法为英国的初级胆道胆炎 (PBC) 患者提供了希望,这些患者对ursodeoxycholic acid (UDCA) 没有反应. 这次审查涵盖了它们的机制,安全性和英国的可访问性.

科学领域:

肝病学肝病学是一种肝病学.
自免疫性肝脏疾病自免疫性肝脏疾病
药理学药理学是指药理学的学科.

背景情况:

初级胆道胆炎 (PBC) 是一种慢性自身免疫性肝病,导致胆道损伤和胆.
它主要影响中年女性,表现为疲劳,和肝酶异常.
乌尔苏多氧胆酸 (UDCA) 是标准的第一线治疗,但许多患者缺乏足够的生化反应.

研究的目的:

审查英国PBC新兴的二线治疗方法.
讨论elafibranor和seladelpar,包括它们的机制,管理和安全性.
探索临床影响,NHS可访问性和辅助症状管理策略.

主要方法:

最近的临床试验和监管批准的文献审查.
对elafibranor和seladelpar特性和英国监管地位的分析.
讨论当前的治疗指南和未来的治疗方向.

主要成果:

伊拉非布拉诺和塞拉德帕代表了UDCA不耐受或不响应PBC患者的新疗法选择.
这些药物提供了新的作用机制来解决胆固醇和肝损伤的问题.
它们在英国的批准扩大了治疗选择,关注NHS整合和症状管理.

结论:

对于PBC的治疗环境正在不断发展,新的药物为非响应者提供了更好的治疗结果.
了解elafibranor和seladelpar的特征对于优化患者护理至关重要.
及时的专家转诊和基于证据的决策是管理PBC进展的关键.

关键词:

这是一种自身免疫性疾病.自免疫性肝病是一种自身免疫性肝病.胆固醇性肝病是一种肝病.这是elafibranor.肥乙醇酸是什么肥乙醇酸主要胆道胆炎 (PBC) 是一种主要的胆道胆炎.第二线药物是药物.塞拉德帕尔 (塞拉德帕尔) 是一个位于西兰的公园.乌尔索多氧胆酸是什么意思

更多相关视频

Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery

Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery

Published on: March 28, 2025

相关概念视频

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...